๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage

Recruitingn/aAges 18 Years - 80 YearsAllBeijing Tiantan Hospital
NCT06906432 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored. In this study, we propose to enroll patients with

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patients aged 18 years or older at the time of enrollment. 2. Acute intracranial hemorrhage confirmed by neuroimaging (CT, MRI๏ผŒCTA, MRA, or DSA) within 48 hours of symptom onset. 3. Ability to provide informed consent or have a legally authorized representative willing to consent on their behalf. Exclusion Criteria: 1. Patients who refuse to participate in the study or cannot provide informed consent. 2. Patients with a history of significant cardiovascular disease, including myocardial infarction, heart failure, or arrhythmias, unless stable and well-controlled. 3. Patients who have undergone cardiac bypass surgery, stent placement, or other cardiovascular interventions within the past 6 months. 4. Patients with active brain tumors, ischemic stroke within 3 months or a history of previous brain injury that could confound the study findings. 5. Patients with active malignant disease, severe inflammatory or infectious disease, or those who have undergone surgery for any reason within the past 3 months. 6. Patients with any condition that, in the opinion of the investigator, would make it unsafe or impractical to participate in the study.
๐Ÿ’Š

What it tests

  • Multi-disciplinary assessment
๐Ÿ“

Where

1 site
Beijing Tiantan Hospital Affiliated to Capital Medical University
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy